A BSTRACT Background: Common first-line antiepileptic drugs (AEDs) used in children are valproate, phenytoin, and levetiracetam. Many side effects for these AEDs are reported including obesity, atherosclerosis, and metabolic syndrome. The aim of our study was to evaluate changes in carotid artery intima-media thickness (CIMT) in epileptic children and to correlate with lipid profile of those who are on long-term antiepileptic therapy. Materials and Methods: This case–control study was done over 18 months in department of pediatrics. Sample size was 84 with equal number of cases and controls. Epileptic children between 1 and 18 years of age receiving monotherapy with valproate, phenytoin, or levetiracetam for at least 6 months were included in the study. Measurement of CIMT was done by B mode ultrasonography. Lipid profile was analyzed. Statistical analysis was performed using one-way analysis of variance (ANOVA) test and Pearson correlation. Results: Among 42 cases of epilepsy, 30 were on valproate, 9 on phenytoin, and 3 on levetiracetam monotherapy. No significant difference was noted in body mass index (BMI) among children receiving AED compared with that of controls ( P = 0.82). Mean value for CIMT was significantly higher among valproate (0.43 ± 0.04, P ≤ 0.001), phenytoin (0.44 ± 0.04, P ≤ 0.001), and levetiracetam group (0.43 ± 0.03, P = 0.01) compared to controls (0.39 ± 0.01). Significant correlation was noted between CIMT and total cholesterol ( P = 0.034), triglyceride ( P = 0.011), low-density lipoprotein ( P = 0.008), and very low-density lipoprotein ( P = 0.011). Conclusion: Children on long-term monotherapy with valproate, phenytoin, and levetiracetam have significantly abnormal CIMT. This might be associated with atherosclerotic changes, and these children may require close follow-up to prevent cardiovascular and cerebrovascular risks.

This study was designed to assess iodine status of mother-fetus dyad by estimation of spot urine iodine concentration (UIC) in the study district. It is a cross-sectional study of 250 pregnant women with euthyroid status and their term neonates residing in Dakshina Kannada district. Neonates with foetal growth restriction or requiring intensive care were excluded. Median UIC was quantified using modified Sandell-Kolthoff reaction by microplate method. World Health Organization (WHO) classification was used to categorise the iodine status of pregnant women. Among 250 pregnant women, the majority were primigravida (38%). Median maternal thyroid stimulating hormone (TSH) was 1.54 mIU/l, and median UIC was 352 mcg/l. Urine iodine levels were insufficient (<150 mcg/l) in 1.2% (n = 3), adequate (150-249 mcg/l) in 9.2% (n = 23) and above requirement (250-499 mcg/l) in 89.6% (n = 224); none had excess (> 500 mcg/l). Median birth weight was 3,000 g and head circumference was 34 cm. Median cord blood TSH was 8.1 mIU/l, and median UIC 344.5 mcg/l. All the newborns had adequate (> 100 mcg/l) iodine status, including those born to mothers with insufficient values. Maternal and newborn median UIC showed positive correlation (r = 0.139; p = 0.028). Iodine statuses were above requirement or adequate in pregnant women from the study district and their neonates, respectively, indicating successful salt iodisation.